Overview of Brenzys

What is Brenzys? (Identity and General Purpose)

Property	Description
Active ingredient	Etanercept
Form	Solution for injection (Prefilled syringe or autoinjector pen)
Pharmacological class	Tumor Necrosis Factor (TNF) inhibitor
Origin	Biosimilar; Recombinant fusion protein
Common purpose	To manage systemic inflammation and disease progression

What Type of Medicine is Brenzys? (Definition and Classification)

Brenzys is a prescription-only biosimilar medicine containing the active ingredient Etanercept, which is classified as a Tumor Necrosis Factor (TNF) inhibitor and a Biologic Disease-Modifying Antirheumatic Drug (bDMARD). The drug is a specialized biological product, manufactured as a recombinant fusion protein. As a biosimilar, Brenzys is highly similar to its reference product, Enbrel, regarding its biological activity and safety profile. The use of these bDMARDs is clinically recognized for controlling severe inflammatory diseases that do not adequately respond to conventional non-biological therapies.

How Does the Etanercept Component Work Generally? (High-Level Purpose)

The general purpose of Brenzys is to manage chronic systemic inflammation by blocking a key inflammatory messenger protein. The Etanercept protein functions as a TNF inhibitor by binding directly to the potent cytokine Tumor Necrosis Factor-alpha (TNF-α). By acting as a decoy, the medicine prevents TNF-α from activating cells, a mechanism known as cytokine blockade. By inhibiting TNF, this mechanism helps to interrupt the destructive cycle of immune-driven inflammation. This targeted biological action helps reduce symptoms like stiffness, swelling, and pain and is intended to slow the underlying progression of the chronic inflammatory disease.

What is the Physical Form of Brenzys? (Composition and Administration Type)

Brenzys is a single-ingredient product supplied as a sterile solution for injection. It is available in a pre-filled syringe and an autoinjector pen, designed for flexible subcutaneous administration. The composition involves the active ingredient Etanercept dissolved in an aqueous solution base. The necessity of the injection route stems from the drug's nature as a delicate protein, which would be rapidly destroyed by the digestive system if taken orally.

Regulatory References

Therapeutic Uses of Brenzys

Brenzys is commonly used to help with conditions characterized by periods of heightened symptoms where systemic inflammation involve inflammatory or irritative processes. This therapy is generally applied when patients whose conditions were previously unresponsive to initial therapies require supportive management.

The medication is relevant for easing symptoms in major conditions, including Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Plaque Psoriasis, as well as specific forms of Juvenile Idiopathic Arthritis in younger patients.

What Brenzys Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed in these systemic inflammatory states. It is relevant for managing symptoms that interfere with daily comfort, specifically symptoms related to physical discomfort, significant swelling, and chronic stiffness in the joints and spine. This use contributes to improved day-to-day comfort and supports patients during episodes of heightened discomfort. It is also applied to address extensive skin manifestations, such as scaly plaques and redness, assisting with maintaining functional stability in both adult and pediatric populations.

Quick Fact: Relief for Chronic Inflammation

The therapy is relevant for easing the overall symptom load and may assist with managing symptoms that create noticeable functional strain, particularly in moderate to severe active disease.

Regulatory References

European Medicines Agency therapeutic overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Brenzys?

The population eligibility for Brenzys (Etanercept biosimilar) is strictly defined by regulatory authorities based on a patient's clinical status and age.

Absolute Contraindications (Must Not Use)

Brenzys is contraindicated and must not be used in patients with known hypersensitivity to Etanercept or any of the product's ingredients. Treatment must also not be started in patients with an active infection, including chronic or localized infections, active tuberculosis (TB), or any risk of sepsis syndrome.

Age and Conditional Eligibility

The medicine is approved for adults (18 years and older). Pediatric eligibility depends on the condition:

Pediatric Use: Approved for Juvenile Idiopathic Arthritis (JIA) in patients 2 years of age or older and for Plaque Psoriasis (PsO) in patients 4 years of age or older.
Older Adults (Geriatric): Use requires caution due to an increased risk of infection in patients over 65.

Conditional use applies to certain comorbidities. Patients must be screened for latent TB and monitored for Hepatitis B reactivation. Caution is necessary for those with a history of congestive heart failure or poorly controlled diabetes.

Pregnancy and Lactation

Use during pregnancy or lactation is a conditional decision, advised only if clearly needed, as the drug crosses the placenta and is present in human milk at low levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Brenzys (Etanercept) is primarily defined by pharmacodynamic interactions related to its effect on the immune system, rather than standard small-molecule metabolic pathways.

Documented Interaction Restrictions

Classification	Interacting Agent	Official Regulatory Statement
Contraindicated	Live Vaccines	Co-administration is prohibited due to the risk of infection from the vaccine and potentially reduced immune response.
Not Recommended	Anakinra	Co-use is not recommended due to an officially documented increased risk of serious infection and neutropenia without added clinical benefit.
Not Recommended	Abatacept	Co-use is not recommended due to an officially documented increased risk of serious infection and other serious adverse events.

Co-administration with other biologic disease-modifying antirheumatic drugs (bDMARDs) is generally not recommended due to the possibility of heightened immunosuppression. Since Etanercept is a large biologic protein, regulatory data confirms that there are no clinically significant pharmacokinetic interactions documented with common small-molecule medications like Methotrexate, NSAIDs, or Glucocorticoids that would alter its plasma concentration. No specific restrictions or formal interactions with food, alcohol, or herbal products are documented in the regulatory labeling. A population-specific caution notes that Etanercept may potentially lower blood glucose in some individuals receiving anti-diabetic medicines, which warrants monitoring.

Mechanism of Action

Decoy Receptor Neutralization of TNF-alpha

Brenzys (Etanercept) functions as a highly specific decoy receptor that binds the pro-inflammatory cytokine Tumor Necrosis Factor-alpha ( TNF-alpha) and Lymphotoxin-alpha ( LT-alpha). Etanercept's engineered protein structure competitively inhibits these mediators by neutralizing their biological activity in circulation. This action prevents the cytokine from binding to cellular receptors, which stops TNF-alpha from initiating cellular signaling.

Modulation of NF-kappa B Inflammatory Signaling

The molecular consequence of TNF-alpha neutralization is the modulation of the intracellular inflammatory signaling sequence in immune and non-immune cells. By limiting TNF-alpha receptor activation, the drug restricts the initiation of signal transduction pathways, specifically the NF-kappa B cascade. This diminished signaling alters the expression of secondary inflammatory mediators like IL-6, resulting in a reduction of the chronic inflammatory amplification loop.

Affecting Connective Tissue Breakdown

This downstream effect focuses on the physiological consequence of reduced TNF-alpha signaling on tissue structure. Lowered TNF-alpha signaling correlates with the suppression of enzymes, such as Matrix Metalloproteinases ( MMPs), which are involved in connective tissue breakdown. This biological adjustment affects tissue structural integrity by altering the impact of excessive mediator activity on tissue architecture.

Dosage and Administration Information

Administration and Dosing Guidelines

Brenzys is a biosimilar biologic administered via subcutaneous injection (under the skin) using a pre-filled syringe or auto-injector. This medication should be administered at the same time each week as directed by a healthcare professional. Patients may self-inject only after receiving comprehensive training on the proper technique.

Official Dosing Schedule

Patient Population	Recommended Dose and Frequency
Adults (RA, PsA, AS)	50 mg once weekly
Adults (Plaque Psoriasis)	Starting Dose: 50 mg twice weekly for the first three months. Maintenance Dose: 50 mg once weekly thereafter.
Pediatric JIA/PsO (≥ 63 kg)	50 mg once weekly
Pediatric JIA/PsO (< 63 kg)	0.8 mg/kg once weekly (maximum 50 mg)

Preparation and Procedural Steps

Warming: Allow the auto-injector or syringe to reach room temperature for approximately 15 to 30 minutes before use. Do not remove the cap or heat the device. Immediate use is recommended once room temperature is achieved.
Inspection: Visually inspect the solution. It should appear clear or slightly opalescent, colorless, or pale yellow. The presence of small, white or nearly transparent protein particles is acceptable; however, do not use the product if it is discolored, cloudy, or contains foreign particulate matter.
Injection Sites: The injection should be administered to the thigh, abdomen, or the back of the upper arm. The site must be alternated with each new injection, ensuring the new site is at least 3 cm away from the previous one. Avoid injecting into skin that is bruised, scarred, or irritated.

Missed Dose Instructions

If a dose is missed, it should be injected as soon as it is remembered. If it is within 48 hours of the next scheduled dose, skip the missed dose and take the next dose at the regularly scheduled time. Do not administer a double dose to compensate for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Brenzys

The research supporting the use of Brenzys, a biosimilar containing the active ingredient etanercept, consists of studies conducted directly with Brenzys or an equivalent biosimilar, along with the extensive body of evidence accumulated over many years for the reference product. This evidence describes what was observed about the medication in specific clinical evaluations.

Evidence for use in Rheumatoid Arthritis (RA)

The core research for the biosimilar involved short-term, randomized controlled trials (RCTs) in adult populations. These studies were used to explore the similarity between the biosimilar and its reference product. Researchers applied standardized tools to measure clinical response and tracked changes in disease activity scores in adults with moderate to severe RA. The overall research base includes numerous RCTs for the reference product where evaluation was conducted against placebo and conventional treatments. Reports described patterns observed in the studies related to outcomes reflecting physical discomfort and daily functioning.

Evidence for use in Psoriatic Arthritis (PsA) and Plaque Psoriasis (PsO)

For Plaque Psoriasis, researchers conducted dedicated Phase 3 comparative RCTs in adults. Studies monitored high-level outcomes related to skin clearance (PASI scores) and overall physician assessment. Reports described patterns that aligned with the predetermined criteria for demonstrating therapeutic equivalence to the reference product over the study period.

For Psoriatic Arthritis, the evidence relies primarily on the extensive RCTs and meta-analyses of the reference product, which explored outcomes in adult patients tracking both joint symptoms and skin manifestations. The regulatory determination for the biosimilar in PsA is based on extrapolation from the robust findings in the RA and PsO equivalence studies.

Evidence for use in Ankylosing Spondylitis (AS)

Research exploring the use of etanercept in Ankylosing Spondylitis (AS) primarily involved short-term RCTs of the reference product. These studies examined standardized outcomes related to spinal function (BASFI) and disease activity (BASDAI). The biosimilar’s approval for AS is based on the extrapolation principle, meaning the regulatory decision was made without dedicated comparative RCTs in this specific population.

Long-term Follow-up and Durability of Study Outcomes

The evidence landscape includes open-label extension studies that follow patients for intermediate periods (up to two to four years) beyond the initial short-term RCTs. These studies contribute to the broader evidence landscape regarding sustained changes in measured outcomes reflecting daily functioning or activity level.

However, the follow-up durations were limited in the specific biosimilar comparative trials. Therefore, long-term effects are not fully established beyond the observation periods documented in the reference product’s extended studies. The certainty remains low regarding the full range of long-term outcomes and the sustained patterns of observed change measured beyond the intermediate follow-up periods reported in the key studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Brenzys (FAQ)

Q: What is Brenzys used for?

According to the official product information, Brenzys is a treatment used for several chronic inflammatory conditions. These include moderate to severe rheumatoid arthritis in adults, polyarticular juvenile idiopathic arthritis in children aged 2 and older, psoriatic arthritis, and severe axial spondyloarthritis (which covers both ankylosing spondylitis and non-radiographic axial spondyloarthritis).

Q: How does Brenzys work?

Brenzys is a type of medicine known as a biosimilar to etanercept. It works by blocking the action of a naturally occurring protein in the body called Tumour Necrosis Factor (TNF). Since TNF is involved in the inflammatory processes of these diseases, blocking it helps to reduce the inflammation and the associated symptoms.

Q: How long does it take for Brenzys to start working?

Clinical study data generally indicate that a response to Brenzys may be observed within 3 months of initiating treatment. However, the regulatory documents also note that it may take longer for some patients to see the full benefits of the medicine.

Q: Can I get an infection while taking Brenzys?

Studies and official information show that patients using Brenzys may have an increased risk of serious infections. This is because the medicine works by altering part of the body's immune response. The official product information notes that patients should be monitored for signs of infection during treatment.

Q: What should I do if I miss a dose of Brenzys?

If a dose of Brenzys is missed, the official product information describes the procedure, which is to administer the dose as soon as it is remembered. The next dose is typically resumed on the original scheduled day, according to the official dosing guidance. Patients should refer to the full instructions for specific details.

Q: Can I travel with Brenzys?

Regulatory documents state that Brenzys must be stored correctly, specifically in a refrigerator at 2 C to 8 C. The full product information details specific, temporary storage conditions that must be strictly followed if refrigerated storage is briefly unavailable, such as during travel. It is essential to consult the detailed packaging instructions regarding temperature.

Q: Can Brenzys be used with methotrexate?

According to the official product information, Brenzys may be used as a standalone treatment or in combination with methotrexate. This combination therapy is specifically indicated in the regulatory materials for treating adult patients with rheumatoid arthritis.

Q: What is a 'biosimilar' medicine?

A biosimilar is a biological medicine that is highly similar to another already approved biological medicine (the reference product). Regulatory sources confirm that Brenzys is a biosimilar to etanercept, meaning it has shown to be similar in terms of structure, biological activity, efficacy, and safety profile.

How should Brenzys be stored and disposed of?

Storage Requirements

Brenzys must be stored in a refrigerator at a temperature between 2 C and 8 C. It is mandatory to keep the medicine in the original carton to protect it from light.

Do not freeze Brenzys. The product must also be stored out of the reach of children. Once removed from the refrigerator and brought to room temperature, the medicine must not be returned to the refrigerator, as specified in stability guidelines.

Handling and Disposal

The medicine may be stored at room temperature for a single period, typically up to 30 to 60 days depending on the regulatory region, and must be used or discarded within that time. After the injection, the entire single-use syringe or auto-injector must be discarded immediately into an approved sharps container. Do not recap or reuse the device. Disposal of unused or expired product must align with local pharmaceutical waste regulations.

Frequency Classification	Examples of Adverse Reactions (SOC Group)
Very Common (ge 1/10)	Infections, Injection Site Reactions
Common (ge 1/100 to < 1/10)	Headache, Fever, Rash, Allergic Reactions
Uncommon (ge 1/1,000 to < 1/100)	Serious infections (e.g., Sepsis), Anemia, Thrombocytopenia
Rare to Very Rare	Aplastic Anemia, CNS Demyelinating Events, Severe Cutaneous Reactions

Brenzys